0810 GMT - Roche's negative Parkinson trial readout doesn't surprise as the drug candidate had a high development risk all along, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's experimental Parkinson drug prasinezumab showed a numeric delay in slowing motor progression in early-stage Parkinson patients but still missed its primary goal in a mid-stage study. Vontobel estimated potential annual peak sales for 2.5 billion Swiss francs for prasinezumab which it didn't account for in its forecasts due to the high development risk associated with this drug, the analyst says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
December 19, 2024 03:10 ET (08:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。